Anonymous ID: bc3a37 April 23, 2020, 9:55 p.m. No.8905171   🗄️.is 🔗kun   >>5211

>>8905151

>What will those same Dr's and nurses do if the hospitals they work for no longer exist?

 

Maybe time to go back to working only for the patient instead of the hospital, just sayin…

Anonymous ID: bc3a37 April 23, 2020, 10:22 p.m. No.8905292   🗄️.is 🔗kun   >>5325 >>5344 >>5392 >>5438 >>5502

Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment

 

Abstract

 

BACKGROUND AND OBJECTIVE:

Severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is a member of the coronavirus family. Coronavirus infections in humans are typically associated with respiratory illnesses, however viral RNA has been isolated in serum from infected patients. Coronaviruses have been identified as a potential low-risk threat to blood safety. The Mirasol Pathogen Reduction Technology (PRT) System utilizes riboflavin and ultraviolet (UV) light to render blood-borne pathogens noninfectious, while maintaining blood product quality. Here we report on the efficacy of riboflavin and UV light against the pandemic virus SARS-CoV-2 when tested in both plasma and platelets units.

 

MATERIALS AND METHODS:

Stock SARS-CoV-2 was grown in Vero cells and inoculated into either plasma or platelet units. Those units were then treated with riboflavin and UV light. The infectious titers of SARS-CoV-2 were determined by plaque assay using Vero cells. A total of five (n=5) plasma and three (n=3) platelet products were evaluated in this study.

 

RESULTS:

In both experiments the measured titer of SARS-CoV-2 was below the limit of detection following treatment with riboflavin and UV light. The mean log reductions in the viral titers were ≥3.40 and ≥4.53 for the plasma units and platelet units, respectively.

 

CONCLUSION:

Riboflavin and UV light effectively reduced the titer of SARS-CoV-2 in both plasma and platelet products to below the limit of detection in tissue culture. The data suggest that the process would be effective in reducing the theoretical risk of transfusion-transmitted SARS-CoV-2.

 

https://www.ncbi.nlm.nih.gov/pubmed/32311760

Anonymous ID: bc3a37 April 23, 2020, 10:28 p.m. No.8905323   🗄️.is 🔗kun   >>5332 >>5438 >>5502

Irradiation by ultraviolet light-emitting diodes inactivates influenza a viruses by inhibiting replication and transcription of viral RNA in host cell

 

Abstract

Influenza A viruses (IAVs) pose a serious global threat to humans and their livestock, especially poultry and pigs. This study aimed to investigate how to inactivate IAVs by using different ultraviolet-light-emitting diodes (UV-LEDs). We developed sterilization equipment with light-emitting diodes (LEDs) those peak wavelengths were 365 nm (UVA-LED), 310 nm (UVB-LED), and 280 nm (UVC-LED). These UV-LED irradiations decreased dose fluence-dependent plaque-forming units of IAV H1N1 subtype (A/Puerto Rico/8/1934) infected Madin-Darby canine kidney (MDCK) cells, but the inactivation efficiency of UVA-LED was significantly lower than UVB- and UVC-LED. UV-LED irradiations did not alter hemagglutination titer, but decreased accumulation of intracellular total viral RNA in infected MDCK cells was observed. Additionally, UV-LED irradiations suppressed the accumulation of intracellular mRNA (messenger RNA), vRNA (viral RNA), and cRNA (complementary RNA), as measured by strand-specific RT-PCR. These results suggest that UV-LEDs inhibit host cell replication and transcription of viral RNA. Both UVB- and UVC-LED irradiation decreased focus-forming unit (FFU) of H5N1 subtype (A/Crow/Kyoto/53/2004), a highly pathogenic avian IAV (HPAI), in infected MDCK cells, and the amount of FFU were lower than the H1N1 subtype. From these results, it appears that IAVs may have different sensitivity among the subtypes, and UVB- and UVC-LED may be suitable for HPAI virus inactivation.

 

J Photochem Photobiol B. 2018 Dec;189:193-200. doi: 10.1016/j.jphotobiol.2018.10.017. Epub 2018 Oct 29.

https://www.ncbi.nlm.nih.gov/pubmed/30391908

Anonymous ID: bc3a37 April 23, 2020, 10:46 p.m. No.8905417   🗄️.is 🔗kun   >>5438 >>5502

they do love their patents

 

Recent Pat Antiinfect Drug Discov. 2018;13(1):70-88. doi: 10.2174/1872213X11666171108104104.

 

Recent Patents on Light-Based Anti-Infective Approaches.

 

Abstract

 

BACKGROUND:

Antibiotic resistance is one of the most serious health threats to modern medicine. The lack of potent antibiotics puts us at a disadvantage in the fight against infectious diseases, especially those caused by antibiotic-resistant microbial strains. To this end, an urgent need to search for alternative antimicrobial approaches has arisen. In the last decade, light-based anti-infective therapy has made significant strides in this fight to combat antibiotic resistance among various microbial strains. This method includes utilizing antimicrobial blue light, antimicrobial photodynamic therapy, and germicidal ultraviolet irradiation, among others. Light-based therapy is advantageous over traditional antibiotics in that it eradicates microbial cells rapidly and the likelihood of light-resistance development by microbes is low.

 

METHODS:

This review highlights the patents on light-based therapy that were filed approximately within the last decade and are dedicated to eradicating pathogenic microorganisms. The primary database that was used for the search was Google Patents. The searches were performed using the keywords including blue light, antimicrobial photodynamic therapy, ultraviolet irradiation, antibiotic resistance, disinfection, bacterium, fungus, and virus.

 

RESULTS:

Forty-five patents were obtained in our search: 9 patents for the antimicrobial blue light approach, 21 for antimicrobial photodynamic therapy, 11 for UV irradiation, and lastly 4 for other light-based anti-infective approaches. The treatments and devices discussed in this review are interestingly enough able to be used in various different functions and settings, such as dental applications, certain eye diseases, skin and hard surface cleansing, decontamination of internal organs (e.g., the stomach), decontamination of apparel and equipment, eradication of pathogenic microorganisms from buildings and rooms, etc. Most of the devices and inventions introduce methods of destroying pathogenic bacteria and fungi without harming human cells and tissues.

 

CONCLUSIONS:

Light-based antimicrobial approaches hold great promise for the future in regards to treating antibiotic-resistant infections and related diseases.